Detalhe da pesquisa
1.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37363867
2.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35108374
3.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34086865
4.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
Inglês
| MEDLINE | ID: mdl-32206772
5.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32107341
6.
Mutations driving CLL and their evolution in progression and relapse.
Nature
; 526(7574): 525-30, 2015 Oct 22.
Artigo
Inglês
| MEDLINE | ID: mdl-26466571
7.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30982686
8.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31868632
9.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Blood
; 131(9): 955-962, 2018 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29255066
10.
IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.
Blood
; 132(21): 2280-2285, 2018 11 22.
Artigo
Inglês
| MEDLINE | ID: mdl-30282799
11.
Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.
Blood
; 130(18): 2027-2031, 2017 11 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28827408
12.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Haematologica
; 104(5): 955-962, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30514803
13.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol
; 2024 Apr 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38578022
14.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(9): 1215-1228, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30115596
15.
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Blood
; 127(2): 208-15, 2016 Jan 14.
Artigo
Inglês
| MEDLINE | ID: mdl-26486789
16.
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Lancet
; 388(10044): 565-75, 2016 Aug 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27313086
17.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24401022
18.
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
Eur J Haematol
; 98(3): 254-262, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-27862308
19.
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 17(7): 928-942, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27216274
20.
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Blood
; 124(26): 3870-9, 2014 Dec 18.
Artigo
Inglês
| MEDLINE | ID: mdl-25359988